CL2023000477A1 - Proteínas de unión restringidas activadas de forma condicional - Google Patents

Proteínas de unión restringidas activadas de forma condicional

Info

Publication number
CL2023000477A1
CL2023000477A1 CL2023000477A CL2023000477A CL2023000477A1 CL 2023000477 A1 CL2023000477 A1 CL 2023000477A1 CL 2023000477 A CL2023000477 A CL 2023000477A CL 2023000477 A CL2023000477 A CL 2023000477A CL 2023000477 A1 CL2023000477 A1 CL 2023000477A1
Authority
CL
Chile
Prior art keywords
binding proteins
conditionally activated
restricted binding
activated restricted
conditionally
Prior art date
Application number
CL2023000477A
Other languages
English (en)
Inventor
B Dubridge Robert
Timothy Chen Tseng-Hui
A Culp Patricia
Michael May Chad
Dettling Danielle
Degenhardt Jeremiah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of CL2023000477A1 publication Critical patent/CL2023000477A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

PROTEÍNAS DE UNIÓN RESTRINGIDAS ACTIVADAS DE FORMA CONDICIONAL; COMPOSICIÓN FARMACEÚTICA; Y SUS USOS.
CL2023000477A 2020-08-17 2023-02-16 Proteínas de unión restringidas activadas de forma condicional CL2023000477A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17

Publications (1)

Publication Number Publication Date
CL2023000477A1 true CL2023000477A1 (es) 2023-11-10

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023000477A CL2023000477A1 (es) 2020-08-17 2023-02-16 Proteínas de unión restringidas activadas de forma condicional

Country Status (16)

Country Link
US (1) US20240026011A1 (es)
EP (1) EP4196503A2 (es)
JP (1) JP2023538366A (es)
KR (1) KR20230048146A (es)
CN (1) CN116419925A (es)
AR (1) AR123266A1 (es)
AU (1) AU2021329290A1 (es)
CA (1) CA3191431A1 (es)
CL (1) CL2023000477A1 (es)
CO (1) CO2023002164A2 (es)
EC (1) ECSP23018458A (es)
IL (1) IL300598A (es)
MX (1) MX2023002002A (es)
PE (1) PE20230856A1 (es)
TW (1) TW202214707A (es)
WO (1) WO2022040128A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023164551A1 (en) * 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2845029A1 (en) 2011-08-17 2013-02-21 Glaxo Group Limited Modified proteins and peptides
SG11201807548SA (en) 2016-03-08 2018-09-27 Maverick Therapeutics Inc Inducible binding proteins and methods of use
IL273119B2 (en) 2017-09-08 2023-10-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
CN114390938A (zh) * 2019-03-05 2022-04-22 武田药品工业有限公司 受约束的条件性活化的结合蛋白

Also Published As

Publication number Publication date
EP4196503A2 (en) 2023-06-21
CN116419925A (zh) 2023-07-11
IL300598A (en) 2023-04-01
AU2021329290A1 (en) 2023-04-13
KR20230048146A (ko) 2023-04-10
US20240026011A1 (en) 2024-01-25
CO2023002164A2 (es) 2023-03-07
MX2023002002A (es) 2023-07-06
WO2022040128A2 (en) 2022-02-24
WO2022040128A3 (en) 2022-04-07
PE20230856A1 (es) 2023-05-29
AR123266A1 (es) 2022-11-16
CA3191431A1 (en) 2022-02-24
TW202214707A (zh) 2022-04-16
JP2023538366A (ja) 2023-09-07
ECSP23018458A (es) 2023-04-28

Similar Documents

Publication Publication Date Title
CL2023000972A1 (es) Inhibidores de ras
CY1124834T1 (el) Αναστολεις της αλληλεπιδρασης της μηνινης-mll
CL2023000973A1 (es) Inhibidores de ras
CL2023000974A1 (es) Inhibidores de ras
BR112018012707A2 (pt) inibidores da interação de menin-mll
CO2020001823A2 (es) Conjugados de citoquina para el tratamiento de enfermedades autoinmunes
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
BR112018068703A2 (pt) inibidores substituídos de menin-mll e métodos de uso
DOP2018000245A (es) Proteinas de fusion gdf15 y usos de estas
CL2019000424A1 (es) Anticuerpos anti-tigit, anticuerpos anti-pvrig y combinaciones de estos.
DK3849614T3 (da) Interleukin-2-polypeptidkonjugater og anvendelser deraf
BR112019005030A2 (pt) inibidores da interação de menina-llm
CO2020010303A2 (es) Conjugados de il-15, y sus usos
BR112019012343A2 (pt) anticorpos il-11ra
EA201170242A1 (ru) Модифицированные бычьи полипептиды g-csf и их применение
AR059978A1 (es) Composiciones farmaceuticas
BR112019017403A2 (pt) composições e métodos para o tratamento de câncer
EA202191806A1 (ru) Антитело против человеческого il-4ra и его применение
BR112017004444A2 (pt) novos anticorpos anti-mfi2 e métodos de uso
CL2021002656A1 (es) Compuestos de pirrolotriazina, inhibidores selectivos de proteínas quinasas kit y pdgfralfa; composición y uso.
CL2021000855A1 (es) Replicones basados en alfavirus para la administración de bioterapias.
DOP2017000246A (es) Polipéptidos dirigidos a la fusión de vih
CL2023000477A1 (es) Proteínas de unión restringidas activadas de forma condicional
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
BR112018072699A2 (pt) determinados inibidores de proteína cinase